Alvotech Ordinary Shares ALVO 深 滬
等待開盤 11-04 09:30:00 美东时间
5.03
-2.620
-34.25%
華盛通- 最 高5.87
- 今 開5.81
- 成交量 463.05万股
- 最 低 4.81
- 昨 收 7.65
- 總市值 15.74亿
- 52周最高 13.70
- 市盈率 靜 --
- 換手率 1.48%
- 52周最低 4.81
- 委 比 -83.61%
- 總股本 3.13亿
- 歷史最高 18.00
- 量 比 11.38
- 振 幅 13.86%
- 歷史最低 4.81
- 每 手 1
- 風險率 1.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alvotech Shares Plunge 33% After FDA Flags Issues
Alvotech shares decline after the FDA issues a complete response letter for its Simponi biosimilar, leading to a lower 2025 revenue and EBITDA outlook.
今天 02:17
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Shares of Lucas GC Limited (NASDAQ:LGCL) rose sharply in pre-market trading aft...
11-03 18:09
Alvotech CCO Anil Okay steps down to become Adalvo CEO
Alvotech (NASDAQ:ALVO) on Wednesday announced changes to its global business development and commercial operations team. Anil Okay, Chief Commercial Officer, is stepping down to serve as Chief Executi...
10-22 20:13
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
Alvotech announced changes to its global business development and commercial operations team. Anil Okay is stepping down as Chief Commercial Officer to lead Adalvo. Trisha Durant has joined as Senior Vice President, Global Business Development and Commercial Operations, ex-North America. Harshika Sarbajna is now Senior Vice President Commercial, North America. Agne Pasko has been appointed Vice President Head of Business Development. Róbert Wessm...
10-22 09:00
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
Morgan Stanley Upgrades Alvotech to Overweight, Announces $14 Price Target
Morgan Stanley analyst Thibault Boutherin upgrades Alvotech (NASDAQ:ALVO) from Equal-Weight to Overweight and announces $14 price target.
10-14 20:54
Alvotech’s AVT23 Biosimilar Gains EMA Acceptance
Alvotech ( ($ALVO) ) just unveiled an announcement. On October 6, 2025, Alvotec...
10-06 20:28
2. Advanz Pharma, Alvotech Move Closer To Launching Affordable Asthma And Allergy Treatment In Europe After EMA Filing Acceptance
Advanz Pharma Holdco Limited ("Advanz Pharma"), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ:ALVO), a global
10-06 16:45
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
Advanz Pharma and Alvotech announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair® (omalizumab). AVT23 aims to improve access to affordable biologic medicines for patients with severe asthma, chronic urticaria, and nasal polyps. Alvotech developed AVT23 in collaboration with Kashiv BioSciences LLC, and Advanz Pharma holds commercial rights in multiple regi...
10-06 08:40
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
